

Amendments to the Claims:

Please cancel claims 28, 39-42, and 45-48 without prejudice.

Please amend claims 20, 30, 35, 43, and 44 as follows:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. – 19. (Cancelled)

20. **(Currently amended)** A method for diagnosing colon cancer comprising detecting ~~evidence of~~ differential expression of PPP3CC in a patient colon sample, wherein ~~evidence of~~ differential expression is detected by measuring the level of an expression product of PPP3CC; said expression product ~~at least 98% identical to~~ having the nucleotide sequence of SEQ ID NO:1587; wherein an increase in the level of the expression product in the sample of at least 50% relative to a non-cancerous control is indicative of colon cancer ~~and wherein the expression product encodes a polypeptide with protein phosphatase activity.~~

21. – 29. (Cancelled)

30. **(Currently amended)** The method of claim 20 wherein the non-cancerous control is a ~~known normal~~ tissue of the same tissue type as in the patient sample.

31. (Cancelled)

32. **(Previously presented)** The method of claim 20 wherein the level of the expression product in the sample is increased at least 100% relative to the control.

33. **(Previously presented)** The method of claim 20 wherein the level of the expression product in the sample is increased at least 150% relative to the control.

34. **(Cancelled)**

35. **(Currently amended)** A method of diagnosing lymphoma, colon cancer, or stomach cancer ~~or breast cancer~~ comprising:

a) determining the expression level of ~~an expression product~~ a nucleic acid comprising ~~[[a]] the~~ nucleotide sequence of SEQ ID NO:1587, ~~or a full complement thereof~~, in a patient sample; and

b) comparing said level of the ~~expression product~~ nucleic acid in (a) to a level of the ~~expression product~~ nucleic acid in a second sample, said second sample comprising a ~~normal~~ non-cancerous tissue, wherein a difference between the level of the ~~expression products~~ nucleic acid in (a) and the level of the ~~expression products~~ nucleic acid in the second sample indicates that the patient has lymphoma, colon cancer, or stomach cancer ~~or breast cancer~~.

36. – 42. **(Cancelled)**

43. **(Currently amended)** A method for diagnosing colon cancer comprising comparing levels of PPP3CC protein in a patient colon sample to that of a non-cancerous colon control sample, wherein the PPP3CC protein is encoded by a nucleic acid having the nucleotide sequence set forth in SEQ ID NO:1587, wherein an increase in the level of PPP3CC protein in the patient colon sample of at least 50% relative to ~~[[a]]~~ said non-cancerous colon control is indicative of colon cancer.

44. **(Currently amended)** A method for diagnosing colon cancer comprising comparing levels of a polypeptide encoded for by a nucleic acid comprising a nucleotide sequence at least 98% identical to SEQ ID NO:1587 in a patient colon sample to a non-cancerous colon control sample, wherein an increase in the level of the polypeptide in the patient colon sample of at least

Applicant : Morris, et al.
Serial No. : 10/035,832
Filed : December 26, 2001
Page : 4 of 11

Attorney's Docket No.: 20366-
027001 / PP023698.0001

50% relative to [[a]] said non-cancerous colon control is indicative of colon cancer, said polypeptide having protein phosphatase activity.

45. – 48. **(Cancelled)**